(Q36654926)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17109028%20AND%20SRC:MED&resulttype=core&format=json

22 December 2019

title

Indications for allogeneic stem cell transplantation in chronic lymphocytic leukemia: the EBMT transplant consensus (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17109028%20AND%20SRC:MED&resulttype=core&format=json

22 December 2019

0 references

1 reference

stem cell transplantation

1 reference

chronic lymphocytic leukemia

inferred from title

1 reference

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17109028%20AND%20SRC:MED&resulttype=core&format=json

22 December 2019

J Schetelig

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17109028%20AND%20SRC:MED&resulttype=core&format=json

22 December 2019

W Wiktor-Jedrzejczak

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17109028%20AND%20SRC:MED&resulttype=core&format=json

22 December 2019

P Dreger

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17109028%20AND%20SRC:MED&resulttype=core&format=json

22 December 2019

E Kimby

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17109028%20AND%20SRC:MED&resulttype=core&format=json

22 December 2019

M Michallet

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17109028%20AND%20SRC:MED&resulttype=core&format=json

22 December 2019

D Milligan

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17109028%20AND%20SRC:MED&resulttype=core&format=json

22 December 2019

D Niederwieser

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17109028%20AND%20SRC:MED&resulttype=core&format=json

22 December 2019

M Hallek

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17109028%20AND%20SRC:MED&resulttype=core&format=json

22 December 2019

E Montserrat

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17109028%20AND%20SRC:MED&resulttype=core&format=json

22 December 2019

Chronic Leukemia Working Party of the EBMT

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17109028%20AND%20SRC:MED&resulttype=core&format=json

22 December 2019

publication date

16 November 2006

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17109028%20AND%20SRC:MED&resulttype=core&format=json

22 December 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17109028%20AND%20SRC:MED&resulttype=core&format=json

22 December 2019

volume

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17109028%20AND%20SRC:MED&resulttype=core&format=json

22 December 2019

issue

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17109028%20AND%20SRC:MED&resulttype=core&format=json

22 December 2019

page(s)

12-17

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17109028%20AND%20SRC:MED&resulttype=core&format=json

Long-term follow-up of patients with CLL treated with allogeneic hematopoietic transplantation

22 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404441

HLA-identical sibling bone marrow transplantation in younger patients with chronic lymphocytic leukemia. European Group for Blood and Marrow Transplantation and the International Bone Marrow Transplant Registry.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404441

Evidence of a graft-versus-leukemia effect in chronic lymphocytic leukemia after reduced-intensity conditioning and allogeneic stem-cell transplantation: the Cooperative German Transplant Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404441

Hematopoietic cell transplantation after nonmyeloablative conditioning for advanced chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404441

Autologous and allogeneic stem cell transplantations for poor-risk chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404441

Clinical significance of minimal residual disease, as assessed by different techniques, after stem cell transplantation for chronic lymphocytic leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404441

Salvage therapy for CLL and the role of stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404441

How I treat refractory CLL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404441

Graft-versus-leukemia activity may overcome therapeutic resistance of chronic lymphocytic leukemia with unmutated immunoglobulin variable heavy-chain gene status: implications of minimal residual disease measurement with quantitative PCR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404441

Results of first salvage therapy for patients refractory to a fludarabine regimen in chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404441

Frequency and type of serious infections in fludarabine-refractory B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma: implications for clinical trials in this patient population

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404441

Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404441

Results of the fludarabine and cyclophosphamide combination regimen in chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404441

Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404441

Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404441

Fludarabine, cyclophosphamide and mitoxantrone in the treatment of resistant or relapsed chronic lymphocytic leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404441

Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404441

Genomic aberrations and survival in chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404441

Select high-risk genetic features predict earlier progression following chemoimmunotherapy with fludarabine and rituximab in chronic lymphocytic leukemia: justification for risk-adapted therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404441

ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404441

Expression of ribosomal and translation-associated genes is correlated with a favorable clinical course in chronic lymphocytic leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404441

In-tandem insight from basic science combined with clinical research: CD38 as both marker and key component of the pathogenetic network underlying chronic lymphocytic leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404441

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404441

Clinical outcomes and prognostic factors in patients with Richter's syndrome treated with chemotherapy or chemoimmunotherapy with or without stem-cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404441

High remission rate in T-cell prolymphocytic leukemia with CAMPATH-1H

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404441

Allogeneic Stem-Cell Transplantation May Overcome the Adverse Prognosis of UnmutatedVHGene in Patients With Chronic Lymphocytic Leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404441

Allogeneic Transplant with Reduced Intensity Conditioning Regimens may Overcome the Poor Prognosis of B-Cell Chronic Lymphocytic Leukemia with Unmutated Immunoglobulin Variable Heavy-Chain Gene and Chromosomal Abnormalities (11q- and 17p-)

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404441

Outcome of allogeneic stem cell transplantation for B cell chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404441

7 January 2021

Minimal residual disease is common after allogeneic stem cell transplantation in patients with B cell chronic lymphocytic leukemia and may be controlled by graft-versus-host disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404441

7 January 2021

Different clinical value of minimal residual disease after autologous and allogeneic stem cell transplantation for chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404441

7 January 2021

Reduced-intensity conditioning lowers treatment-related mortality of allogeneic stem cell transplantation for chronic lymphocytic leukemia: a population-matched analysis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404441

7 January 2021

The prognostic impact of minimal residual disease assessment after stem cell transplantation for chronic lymphocytic leukemia: is achievement of molecular remission worthwhile?

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404441

7 January 2021

Chronic Lymphocytic Leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404441

7 January 2021

Additional genetic high-risk features such as 11q deletion, 17p deletion, and V3-21 usage characterize discordance of ZAP-70 and VH mutation status in chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404441

7 January 2021

ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profile

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404441

7 January 2021

Identifiers

DOI

10.1038/SJ.LEU.2404441

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17109028%20AND%20SRC:MED&resulttype=core&format=json

release_vhsjiimz2betvbdqt3kyslqx4u

22 December 2019

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/vhsjiimz2betvbdqt3kyslqx4u

24 November 2022

mapped directly with Wikidata item

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17109028%20AND%20SRC:MED&resulttype=core&format=json